Ozempic maker’s stock surges. A trial of a new Novo Nordisk drug shows promise.
Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...
Novo Nordisk stock pops on Phase 1 data for new weight loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...
5 Things to Know Before the Stock Market Opens
U.S. stock futures point lower after the major indexes approached or set record highs, Novo Nordisk stock soars on positive weight-loss trial results, and Boeing shares dip after the company projects ...
Novo Shares Soar as Experimental Shot Shows 22% Weight Loss
Novo Nordisk A/S rose the most since August 2023 after its experimental shot delivered as much as 22% weight loss in an early ...
pharmaphorum55m
Novo Nordisk leaps on new obesity drug data
Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...